Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?

Alzheimer's and Dementia

Volumn 2, Issue 2, 2006, Pages 118-125

  Sabbagh, Marwan N ^a   Farlow, Martin R ^b   Relkin, Normal ^c   Beach, Thomas G ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Muscarinic; Prevention; Therapy

Indexed keywords

AF 150; AF 267B; ALVAMELINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETHANECHOL; CARBACHOL; CEVIMELINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DICHLORVOS; DONEPEZIL; GALANTAMINE; GALLAMINE; METRIFONATE; MUSCARINIC AGENT; NICOTINIC RECEPTOR; PHENSERINE; PHYSOSTIGMINE; PLACEBO; RIVASTIGMINE; TACRINE; TALSACLIDINE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG POTENTIATION; ENZYME INHIBITION; FUNCTIONAL ASSESSMENT; HUMAN; LOW DRUG DOSE; META ANALYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SYMPTOMATOLOGY; SYSTEMATIC REVIEW;

EID: 33645756861     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2006.02.001     Document Type: Review

References (98)

1. Perry E.K., Johnson M., Kerwin J.M., et al. Convergent cholinergic activities in aging and Alzheimer's disease. Neurobiol Aging 13 (1992) 393-400
2. Katzman R., Terry R., DeTeresa R., et al. Clinical, pathological, and neurochemical changes in dementia. a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 23 (1988) 138-144
3. Beach T.G., Honer W.G., and Hughes L.H. Cholinergic fibre loss associated with diffuse plaques in the non- demented elderly. the preclinical stage of Alzheimer's disease?. Acta Neuropathol (Berl) 93 (1997) 146-153
4. Beach T.G., Potter P.E., Kuo Y.M., et al. Cholinergic deafferentation of the rabbit cortex. a new animal model of Abeta deposition. Neurosci Lett 283 (2000) 9-12
5. Potter P., Pandya Y., et al. Cortical cholinergic deficit is associated with plaque development at preclinical stages of Alzheimer's disease. Neurobiol Aging 25 S2 (2004) 79
6. Funato H., Yoshimura M., Kusui K., et al. Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease. Am. J. Pathol 152 (1998) 1633-1640
7. Davies L., Wolska B., Hilbich C., et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease. prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 38 (1988) 1688-1693
8. Inestrosa N.C., Alvarez A., Perez C.A., et al. Acetycholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils. possible role of the peripheral site of the enzyme. Neuron 16 4 (1996) 881-891
9. Davis K.L., Mohs R.C., Marin D., et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281 (1999) 1401-1406
10. DeKosky S.T., Ikonomovic M.D., Styren S.D., et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51 (2002) 145-155
11. Wallace W.C., Bragin V., Robakis N.K., et al. Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert. Brain Res Mol Brain Res 10 (1991) 173-178
12. Wallace W., Ahlers S.T., Gotlib J., et al. Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation. Proc Natl Acad Sci U S A 90 (1993) 8712-8716
13. Rossner S., Schliebs R., Hartig W., and Bigl V. 192IGG-saporin-induced selective lesion of cholinergic basal forebrain system. neurochemical effects on cholinergic neurotransmission in rat cerebral cortex and hippocampus. Brain Res Bull 39 (1995) 371-381
14. Lin L., LeBlanc C.J., Deacon T.W., and Isacson O. Chronic cognitive deficits and amyloid precursor protein elevation after selective immunotoxin lesions of the basal forebrain cholinergic system. Neuroreport 9 (1998) 547-552
15. Beach T.G., Walker D., Sue L., et al. Immunotoxin lesion of the cholinergic nucleus basalis causes Ab deposition. towards a physiologic animal model of Alzheimer's disease. Curr Med Chem 3 (2003) 57-75
16. Roher A.E., Kuo Y.M., Potter P.E., et al. Cortical cholinergic denervation elicits vascular A beta deposition. Ann NY Acad Sci 903 (2000) 366-373
17. Beach T.G., Walker D.G., Roher A.E., and Potter P.E. Anti-Amyloidogenic activity of cholinergic agents. Drug Dev Res 56 (2002) 242-247
18. Beach T.G. Muscarinic agonists as preventative therapy for Alzheimer's disease. Curr Opin Investig Drugs 3 (2002) 1633-1636
19. Farias G.G., Godoy J.A., Hernandez F., Avila J., Fisher A., and Inestrosa N.C. M1 muscarinic receptor activation protects neurons from beta-amyloid toxicity. a role for Wnt signaling pathway. Neurobiol Dis 17 (2004) 337-348
20. Holschneider D.P., Waite J.J., Li M.G., and Scremin O.U. Decreased cortical blood flow after intraventricular administration of the 192 IgG-saporin immunotoxin. Soc Neurosci Abs 23 (1997) 1575
21. Buxbaum J.D., Oishi M., Chen H.I., et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci U S A 89 (1992) 10075-10078
22. NitschRM, SlackBE, WurtmanRJ, and GrowdonJH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 28 (1992) 304-307
23. Hung A.Y., Haass C., Nitsch R.M., et al. Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J Biol Chem 268 (1993) 22959-22962
24. Bymaster F.P., Wong D.T., Mitch C.H., et al. Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232). J Pharmacol Exp Ther 269 (1994) 282-289
25. Nitsch R.M., and Growdon J.H. Role of neurotransmission in the regulation of amyloid beta-protein precursor processing. Biochem Pharmacol 47 (1994) 1275-1284
26. Haring R., Gurwitz D., Barg J., et al. Amyloid precursor protein secretion via muscarinic receptors. reduced desensitization using the M1-selective agonist AF102B. Biochem Biophys Res Commun 203 (1994) 652-658
27. Haring R., Gurwitz D., Barg J., et al. NGF promotes amyloid precursor protein secretion via muscarinic receptor activation. Biochem Biophys Res Commun 213 (1995) 15-23
28. Eckols K., Bymaster F.P., Mitch C.H., Shannon H.E., Ward J.S., and DeLapp N.W. The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-m1 cells. Life Sci 57 (1995) 1183-1190
29. Wolf B.A., Wertkin A.M., Jolly Y.C., et al. Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells. J Biol Chem 270 (1995) 4916-4922
30. Muller D.M., Mendla K., Farber S.A., and Nitsch R.M. Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. Life Sci 60 (1997) 985-991
31. Bymaster F.P., Carter P.A., Peters S.C., et al. Compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. Brain Res 795 (1998) 179-190
32. DeLapp N., Wu S., Belagaje R., et al. Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells. Biochem Biophys Res Commun 244 (1998) 156-160
33. Fisher A. Therapeutic strategies in Alzheimer's disease. M1 muscarinic agonists. Jpn J Pharmacol 84 (2000) 101-112
34. Hock C., Golombowski S., Muller-Spahn F., et al. Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity. Eur Neurol 39 (1998) 111-118
35. Muller D., Wiegmann H., Langer U., Moltzen-Lenz S., and Nitsch R.M. Lu 25-109, a combined m1 agonist and m2 antagonist, modulates regulated processing of the amyloid precursor protein of Alzheimer's disease. J Neural Transm 105 (1998) 1029-1043
36. Savage M.J., Trusko S.P., Howland D.S., et al. Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci 18 (1998) 1743-1752
37. Buxbaum J.D., Koo E.H., and Greengard P. Protein phosphorylation inhibits production of Alzheimer amyloid beta/A4 peptide. Proc Natl Acad Sci U S A 90 (1993) 9195-9198
38. Slack B., Nitsch R., Livneh E., et al. Regulation by phorbol esters of amyloid precursor protein release from Swiss 3T3 fibroblasts overexpressing protein kinase C alpha. J Bio Chem 268 (1993) 21097-21101
39. Greig N.H., Sambamurti K., Yu Q.S., Brossi A., Bruinsma G.B., and Lahiri D.K. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res 2 (2005) 281-290
40. Shaw K.T., Utsuki T., Rogers J., Yu Q.S., Sambamurti K., Brossi A., et al. Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci U S A 98 13 (2001) 7605-7610
41. Lahiri D.K., and Farlow M.R. Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell lines. Mol Neurosci 7 1 (1996) 41-49
42. Farber S.A., Nitsch R.M., Schulz J.G., and Wurtman R.J. Regulated secretion of beta-amyloid precursor protein in rat brain. J Neurosci 15 (1995) 7442-7451
43. Mori F., Lai C.C., Fusi F., and Giacobini E. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport 6 (1995) 633-636
44. Chong Y.H., and Suh Y.H. Amyloidogenic processing of Alzheimer's amyloid precursor protein in vitro and its modulation by metal ions and tacrine. Life Sci 59 7 (1996) 545-547
45. Racchi M., Sironi M., Caprera A., Konig G., and Govoni S. Short- and long-term effect of acetylcholinesterase inhibition on the expression and metabolism of the amyloid precursor protein. Mol Psychiatry 6 5 (2001) 520-528
46. Pittel Z., Heldman E., Barg J., Haring R., and Fisher A. Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum. Brain Res 742 (1996) 299-304
47. Haroutunian V., Greig N., Pei X.F., et al. Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Brain Res Mol Brain Res 46 (1997) 161-168
48. Beach T.G., KuoY, Schwab C., Walker D.G., and Roher A.E. Reduction of cortical amyloid beta levels in guinea pig brain after systemic administration of physostigmine. ??. Neurosci Lett 310 (2001) 21-24
49. Beach T.G., Walker D.G., Potter P.E., Sue L.I., and Fisher A. Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists. Brain Res 905 (2001) 220-223
50. Nitsch R.M., Deng M., Tennis M., Schoenfeld D., and Growdon J.H. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 48 (2000) 913-918
51. Hock C., Maddalena A., Raschig A., et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid 10 (2003) 1-6
52. Basun H., Nilsberth C., Eckman C., Lannfelt L., and Younkin S. Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine. Dement Geriatr Cogn Disord 14 (2002) 156-160
53. Lahiri D.K., Farlow M.R., and Sambamurti K. The secretion of amyloid beta-peptide is inhibited the tacrine-treated human neuroblastoma cells. Brain Res Mol Brain Res 2 2 (1998) 131-140
54. Zimmerman M., Gardoni G., Marcello E., Colciaghi E., et al. Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J Neurochem 90 6 (2004) 1489-1499
55. Boronni B., Colchiaghi F., Pastorino L., Pettenati C., et al. Amyloid precursor protein in platelets of patients with Alzheimer's disease. effect of acetycholinesterase inhibitor treatment. Arch Neurol 58 3 (2001) 442-446
56. Borroni B., Colchiaghi F., Pastorino L., Archetti S., et al. ApoE genotype influences the biological effect at donepezil on APP metabolism in Alzheimer disease. evidence from a peripheral model. Eur Neuropsychopharmacol 12 3 (2002) 195-200
57. Liu H.C., Chi C.W., Ko S.Y., Want H.C., et al. Cholinesterase inhibitor affects the amyloid precursor protein isoforms in patients with Alzheimer's disease. Dementia Geriatr Cogn Disord 19 5-6 (2005) 345-348
58. Hellstrom-Lindahl E., Court J., Keverne J., et al. Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. Eur J Neurosci 19 (2004) 2703-2710
59. Nordberg A., Hellstrom-Lindahl E., Lee M., et al. Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J Neurochem 81 (2002) 655-658
60. Arias E., Gallego-Sandin S., Villaroya M., Garcia A.G., and Lopez M.G. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells. roll of nicotinic receptors. J Pharmacol Exp Ther 315 3 (2005) 1346-1353
61. Arias E., Ales E., Gabilan N.H., Cano-Abad M.D., Villaroya M., Garcia A.G., et al. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin. involvement of nicotinic acetylcholine receptors. Neuropharmacology 46 1 (2004) 103-114
62. Kihara T., Sawada H., Nakmizo T., Kanki R., Yamashita H., Maelicke A., et al. Galantamine modulate nicotinic receptor and blocks Abeta-enhanced glutamate toxicity. Biochem Biophys Res Commun 325 3 (2004) 976-982
63. Bullock R., and Dengiz A. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract 59 7 (2005) 817-822
64. Stern R.G., Mohs R.C., Davidson M., et al. A longitudinal study of Alzheimer's disease. measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 151 3 (1994) 390-396
65. Doraiswamy P.M., Kaiser L., Bieber F., and Garman R.L. The Alzheimer's Disease Assessment Scale. evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer Dis Assoc Disord 15 4 (2001) 174-183
66. Doody R.S., Dunn J.K., Clark C.M., et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord 12 4 (2001) 295-300
67. Winblad B., Engedal K., Soininen H., et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57 3 (2001) 489-495
68. Matthews H.P., Korbey J., Wilkinson D.G., and Rowden J. Donepezil in Alzheimer's disease. eighteen months from Southampton Memory Clinic. Int J Geriatric Psychiatry 15 (2000) 713-720
69. Rogers S.L., and Friedhoff L.T. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease. interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 8 (1998) 67-75
70. Doody R., Geldmacher D., Gordon B., et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 58 (2001) 427-433
71. Rogers S.L., Doody R.S., Pratt R.D., and Ieni J.R. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease. final analysis of a US multicentre open label extension study. Eur Neuropsychopharmacol 10 (2000) 195-203
72. Farlow M., Potkin S., Koumaras B., Veach J., and Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Arch Neurol 60 6 (2003) 843-848
73. Leber P. Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord 10 suppl1 (1996) 31-35
74. Small G.W., Kaufer D., Mendiondo M.S., Quarg P., and Spiegel R. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 59 4 (2005) 473-477
75. Rainer M., and Mucke H.A.M. Int J Geriatr Psychopharmacol 1 (1998) 197-201
76. Grossberg C., Irwin P., Satlin A., Mesenbrink P., and Spiegel R. Rivastigmine in Alzheimer disease. efficacy over two years. Am J Geriatr Psychiatry 12 4 (2004) 420-431
77. Small G.W., Kaufer D., Quarg P., and Spiegel R. Poster presented at the 9th ICADRD. Neurobiol Aging 25 S2 (2004) 79
78. Tariot P.N., and Kershaw P. Galantamine demonstrates cognitive benefits in patients with AD for at least 18 months. Neurology 58 (2002) A277-A278
79. Pirttila T., Wilcock G., Truyen L., and Damaraju C.V. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease. multicenter trial. Eur J Neurol 11 11 (2004) 734-741
80. Raskind M.A., Peskind E.R., Truyen L., Kershaw P., and Damaraju C.V. The cognitive benefits of galantamine are sustained for at least 36 months. Arch Neurol 61 (2004) 252-256
81. Farlow M.R., Lilly M.L., and ENA 713 B352 Study Group. Rivastigmine. an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BMC Geriatrics 5 1 (2005) 3
82. Thal L.J., Carta A., Clarke W.R., Ferris S.H., et al. A 1-year multicenter, placebo-controlled study of acetyl-l-carnitine in patients with Alzheimer's disease. Neurology 47 3 (1996) 705-711
83. Thal L.J., Calvani M., Amato A., and Carta A. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology 55 6 (2000) 805-810
84. Aisen P.S., Davis K.L., Berg J.D., Schafer K., et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 54 3 (2000) 588-593
85. Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression. a randomized controlled trial. JAMA 289 21 (2003) 2819-2826
86. Reines S.A., Block G.A., Morris J.C., et al. Rofecoxib. no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62 1 (2004) 66-71
87. Gilman S., Koller M., Black R.S., Jenkins L., et al. Clinical effects of Abeta immunization (AN1792) 64 9 (2005) 1553-1562
88. Petersen R.C., Thomas R.G., Grundman M., et al., Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352 23 (2005) 2379-2388 Epub 2005 Apr 13
89. Courtney C., Farrell D., Gray R., Hills R., et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease AD 2000. randomised double-blind trial. Lancet 363 9427 (2004) 2105-2115
90. Krishnan K.R.R., Charles H.C., Doraiswamy P.M., et al. Randomized, placebo controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 160 (2003) 2003-2011
91. Hashimoto M., Kazui H., Matsumoto K., Nakano Y., Yasuda M., and Mori E. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?. Am J Psychiatry 162 4 (2005) 676-682
92. Tune L.E., Hoffman J.M., Tisco P.J., et al. Donepezil HCL maintains global glucose activity in patients with Alzheimer's disease; results of a 24 weeks study. J Cereb Blood Flow Metab 19 suppl 1 (1999) 5838
93. Potkin S.G., Anand R., Fleming K., Alva G., et al. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int J Neuropsychopharmacol 4 3 (2001) 223-230
94. Stefanova E., Wall A., Almkvist O., et al. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. J Neural Transmission (2005) July 29[epub ahead of print].
95. Mega M.S., Dinov I.D., Porter V., Chow G., et al. Metabolic patterns associated with the clinical response to galantamine therapy. a fluorodeoxyglucose f18 positron emission tomographic study. Arch Neurol 62 5 (2005) 721-728
96. Knopman D., Schneider L., Davis K., et al. Long-term tacrine (Cognex) treatment. effects on nursing home placement and mortality, Tactrine Study Group. Neurology 47 1 (1996) 166-177
97. Geldmacher D., Provenzanok G., McRae T., et al. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Ger Soc 51 (2003) 937-944
98. Lopez O.L., Becker J.T., Saxton J., Sweet R.A., Klunk W., and DeKosky S.T. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition 53 1 (2005) 83-87